SIRPA and non-small cell lung carcinoma: In solid tumors specifically, SIRPα antagonists, both as monotherapy (16.2% versus 2.8%) and in combination (28.3% versus 3%), yielded higher ORRs than CD47 mAbs, with responses observed in head and neck, colorectal, endometrial, ovarian, liver, NSCLC, and gastric cancer patients.